Meritain Health policies, page 94

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

5,481 public policies Substrate tracks for Meritain Health, by title.

Meritain Health policies
PolicyDetailsCodesSource
Arcalyst SGM 1800-A P20261800-A P2026 · Commercial—Original policy ↗
Arikayce SGM 3150-A P2026a3150-A P2026a · Commercial—Original policy ↗
Asparlas 2833-A SGM P20212833-A · Commercial—Original policy ↗
Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza)0909 · Commercial46Original policy ↗
Atopic Dermatitis Enhanced SGM Adbry 5520-A P20235520-A · Commercial—Original policy ↗
Atopic Dermatitis Enhanced SGM Cibinqo 5521-A P20235521-A · Commercial—Original policy ↗
Atopic Dermatitis Enhanced SGM Cibinqo 5521-A P2024a5521-A P2024a · Commercial—Original policy ↗
Atopic Dermatitis Enhanced SGM Rinvoq 5522-A P2024a5522-A P2024a · Commercial—Original policy ↗
Atopic Dermatitis Enhanced SGM Rinvoq 5522-A P20265522-A · Commercial—Original policy ↗
Attended Electroencephalographic (EEG) Video Monitoring0322 · Commercial18Original policy ↗
Attention Deficit/Hyperactivity Disorder0426 · Commercial188Original policy ↗
Aural Rehabilitation0034 · Commercial7Original policy ↗
Autologous Chondrocyte Implantation0247 · Commercial18Original policy ↗
Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation0599 · Commercial12Original policy ↗
Automated Ambulatory Blood Pressure Monitoring0025 · Commercial11Original policy ↗
Autonomic Testing / Sudomotor Tests0485 · Commercial5Original policy ↗
Autotransfusers and Red Blood Cell Genotyping0639 · Commercial19Original policy ↗
Back Pain - Noninvasive Treatments0232 · Commercial11Original policy ↗
Bafiertam SGM 3881-A P2024_R3881-A · Commercial—Original policy ↗
Balloon Valvuloplasty0477 · Commercial14Original policy ↗
Balloon-Expandable Venous Stents0531 · Commercial10Original policy ↗
Bathroom and Toilet Equipment and Supplies0429 · Commercial35Original policy ↗
Behavioral Vision Therapy and Vision Restoration Therapy0321 · Commercial2Original policy ↗
Benign Skin Lesion Removal0633 · Commercial22Original policy ↗
Beta Agonists-Long Acting, Combinations Oral Inhalation Limit 34-H P09-2024_RP09-2024_R · Commercial—Original policy ↗
Betibeglogene Autotemcel (Zynteglo)1016 · Commercial18Original policy ↗
Bimzelx SGM 6220-A P20256220-A · Commercial—Original policy ↗
Bio-Surgery: Medicinal Leech Therapy and Medical Maggots0556 · Commercial3Original policy ↗
Biochemical Markers of Bone Remodeling0562 · Commercial16Original policy ↗
Biofeedback0132 · Commercial12Original policy ↗
Bone and Tendon Graft Substitutes and Adjuncts0411 · Commercial86Original policy ↗
Bone Growth Stimulators0343 · Commercial8Original policy ↗
Bone-Anchored Hearing Aids0403 · Commercial42Original policy ↗
Botulinum Toxin0113 · Commercial40Original policy ↗
Bowel Management Devices0522 · Commercial9Original policy ↗
BPH Cialis 2.5mg, 5mg PA with Limit Policy 865-C UDR 05-2023865-C · Commercial—Original policy ↗
Brachytherapy0371 · Commercial54Original policy ↗
Braftovi 2616-A SGM P20222616-A · Commercial—Original policy ↗
Brain Natriuretic Peptide Testing0618 · Commercial19Original policy ↗
Breast Biopsy Procedures0269 · Commercial61Original policy ↗
Breast Ductal Lavage and Fiberoptic Ductoscopy0517 · Commercial10Original policy ↗
Breast Pumps0421 · Commercial11Original policy ↗
Breast Transillumination, Electrical Impedance Scanning (EIS), and Elastography0386 · Commercial15Original policy ↗
BreastCare/BreastAlert Differential Temperature Sensor0337 · Commercial2Original policy ↗
Brexucabtagene Autoleucel (Tecartus)0980 · Commercial7Original policy ↗
Brush Biopsy - Transepithelial Sample Collection (006)006 · Effective Mar 24, 2025 · Commercial1Original policy ↗
Bunionectomy0629 · Commercial35Original policy ↗
Bupivacaine Liposome (Exparel)0941 · Commercial68Original policy ↗
Buprenorphine Limit, Post PA 2328-HJ P12-20242328-HJ · Commercial—Original policy ↗
Burosumab-twza (Crysvita)0932 · Commercial9Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.